Medtronic Vascular
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Medtronic Vascular sits in the top decile of US sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count).
Medtronic Vascular: 26 sponsored US clinical trials, 3 recruiting.
Medtronic Vascular sponsors 26 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 22 completed. 2 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Vascular Diseases, with 3 trials.
Top-decile sponsor footprint
Medtronic Vascular ranks in the top decile of sponsors by registered trial count (#604 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
22 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
26 total, page 1 of 1
Longitudinal Real-world Clinical Outcomes Study on Symplicity Renal Denervation
NCT07174622
SPYRAL GEMINI Pilot Study
NCT06907147
Prevail Global Study
NCT06535854
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
NCT05198674
SPYRAL DYSTAL Renal Denervation Global Clinical Study
NCT04311086
A Single Arm Trial With Resolute Onyx in ONE-Month DAPT for High-Bleeding Risk Patients Who Are Considered One-Month Clear (Onyx ONE Clear)
NCT03647475
RESOLUTE ONYX Post-Approval Study (Bifurcation Cohort)
NCT03584464
RESOLUTE ONYX Post-Approval Study
NCT03063749
SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System
NCT02439775
Medtronic RESOLUTE ONYX Core (2.25 mm - 4.0 mm) Clinical Study
NCT02419521
SPYRAL PIVOTAL - SPYRAL HTN-OFF MED Study
NCT02439749
Medtronic Resolute Onyx 2.0 mm Clinical Study
NCT02412501
Renal Nerve Denervation in Patients With Hypertension and Paroxysmal and Persistent Atrial Fibrillation
NCT02064764
Renal Denervation in Patients With Uncontrolled Hypertension - SYMPLICITY HTN-4
NCT01972139
Resolute Integrity US Extended Length Sub-Study(RI US XL)
NCT01913600
An Evaluation of the Commercially Available Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
NCT01638507
SYMPLICITY HTN-3 Renal Denervation in Patients With Uncontrolled Hypertension
NCT01418261
EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events
NCT01069003
Sprinter Legend Balloon Catheter
NCT00961311
PROTECT Continued Access Post Marketing Surveillance Trial
NCT00846846
Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension
NCT00753116
Renal Denervation in Patients With Refractory Hypertension
NCT00753285
The Medtronic RESOLUTE US Clinical Trial
NCT00726453
Endeavor Zotarolimus - Eluting Stent in the Treatment Lesions in Small Native Coronary Arteries.
NCT00609947
The ENDEAVOR Pharmacokinetic (PK) Registry: The Medtronic Endeavor Drug Eluting Coronary Stent System
NCT00314275
The ENDEAVOR IV Clinical Trial: A Trial of a Coronary Stent System in Coronary Artery Lesions
NCT00217269
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 4 | 2 |
Therapeutic Areas
Where Medtronic Vascular enrollment is open (later-stage tilt)
3 recruiting of 26 indexed (12% open); 22 completed (85%).
Phase mix: 2 late (III/IV) vs 1 early (I/II) (later-stage heavy).
Top condition: Vascular Diseases (3 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Medtronic Vascular: open-pipeline peers nationwide
Peers matched on 26 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Medtronic Vascular sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 26 trials (± recruiting share)
- Abbott Diabetes Care · 26 trials · 12% recruiting
- Aldeyra Therapeutics · 26 trials · 4% recruiting
- California Polytechnic State University-San Luis Obispo · 26 trials · 19% recruiting
- DexCom · 26 trials · 4% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Midwest Center for Metabolic and Cardiovascular Research · 12% recruiting · 26 trials
- VA Connecticut Healthcare System · 12% recruiting · 26 trials
- Barbara Ann Karmanos Cancer Institute · 12% recruiting · 139 trials
- Janssen Research & Development · 11% recruiting · 593 trials
Related
What to do with this Medtronic Vascular page
26 registered trials is a research-attention snapshot, not an endorsement of Medtronic Vascular or any single study.
- 3 of Medtronic Vascular's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Vascular Diseases is the condition Medtronic Vascular studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Vascular Diseases trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Medtronic Vascular pipeline card: 26 registered trials from official public datasets.Report a data error.